Chronic plaque psoriasis presents clinically as an inflammatory disease of the 
skin, which is often associated with comorbidities and responsible for a poor 
quality of life. It can widely vary among patients because of different age of 
onset, type of symptoms, areas of involvement, and disease severity. The choice 
of the treatment of psoriasis should be personalized according to the specific 
needs of the patients. Apremilast is a well-tolerated and effective 
phosphodiesterase type 4 inhibitor that is indicated for the treatment of 
moderate-to-severe plaque psoriasis and psoriatic arthritis. In this article, 
the pharmacological, clinical, and safety aspects of apremilast are reviewed. 
Based on these data, apremilast could be indicated for patients with a Psoriasis 
Area and Severity Index score <10 but with a significant impact on quality of 
life and seems to be an appropriate treatment for elderly patients also.